A practical guide to the management and prevention of migraine

Drugs

Volumn 56, Issue 5, 1998, Pages 811-824

  Diener, Hans Christoph ^a   Kaube, Holger ^a   Limmroth, Volker ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANALGESIC AGENT; ANTIEMETIC AGENT; ANTIMIGRAINE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIHYDROERGOTAMINE; ELETRIPTAN; ERGOTAMINE; FLUNARIZINE; LISURIDE; METHYSERGIDE; METOPROLOL; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIZOTIFEN; PROPRANOLOL; RIZATRIPTAN; SUMATRIPTAN; VALPROIC ACID; ZOLMITRIPTAN;

HUMAN; MIGRAINE; REVIEW; SIDE EFFECT;

EID: 0031789475     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199856050-00006     Document Type: Review

References (90)

1. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 Suppl. 7: 1-93
2. Joutel A, Bousser M-G, Biousese V, et al. A gene for familial hemiplegic migraine maps to chromosome 19. Nat Genet 1993; 5: 40-5
3. Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1997; 87: 543-52
4. Diener HC, Peatfield RC. Migraine. In: Brandt T, Caplan LR, Dichgans J, et al., editors. Neurological disorders: course and treatment. San Diego: Academic Press, 1996: 1-16
5. 1 receptors in migraine pathophysiology and treatment. Eur J Neurol 1995; 2: 5-21
6. Olesen J. A review of current drugs for migraine. J Neurol 1991; 238 Suppl. 1: S23-7
7. Welch KMA. Drug therapy of migraine. N Engl J Med 1993; 329: 1476-82
8. Goadsby PJ. How do the currently used prophylactic agents work in migraine? Cephalalgia 1907; 17: 85-92
9. Couch JR. Placebo effect and clinical trials in migraine therapy. Neuroepidemiology 1987; 6: 178-85
10. Buzzi G, Sakas DE, Moskowitz MA. Indomethacin and acetylsalicylic acid block neurogenic plasma protein extravasation in rat dura mater. Eur J Pharmacol 1989; 165: 251-8
11. Kaube H, Hoskin KL, Goadsby PJ. Intravenous acetylsalicylic acid inhibits central trigeminal neurons in the dorsal horn of the upper cervical spinal cord in the cat. Headache 1993; 33: 541-4
12. Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group. A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. Eur Neurol 1992; 32: 177-84
13. Tfelt-Hansen P, Henry P, Mulder LJ, et al. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995; 346: 923-6
14. MacGregor EA, Wilkinson M, Bancroft K. Domperidone plus paracetamol in the treatment of migraine. Cephalalgia 1993; 13: 124-7
15. Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992; 13: 307-11
16. Edvinsson L, Goadsby PJ. Neuropeptides in the cerebral circulation: relevance to headache. Cephalalgia 1995; 15: 272-6
17. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993; 33: 48-56
18. Dahlöf C. Placebo-controlled clinical trials with ergotamine in the acute treatment of migraine. Cephalalgia 1993; 13: 166-71
19. Ziegler D, Ford R, Kriegler J, et al. Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology 1994; 44: 447-53
20. Andersson PG. Ergotism: the clinical picture. In: Diener HC, Wilkinson M, editors. Drug-induced headache. Berlin: Springer, 1988: 16-9
21. Diener HC, Wilkinson M, editors. Drug-induced headache. Berlin: Springer, 1988
22. Scholz E, Gerber WD, Diener HC, et al. Dihydroergotamine versus flunarizine versus nifedipine versus metoprolol versus propranolol in migraine prophylaxis: a comparative study based on time series analysis. In: Clifford Rose F, editor. Advances in headache research. London: John Libey and Co., 1987: 135-45
23. 1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine. Cephalalgia 1991; 11: 165-8
24. Ferro A, Longmore J, Hill RG, et al. A comparison of the contractile effects of 5-hydroxytryptamine, sumatriptan and MK-462 on human coronary artery in vitro. Br J Clin Pharmacol 1995; 40: 245-51
25. 1B/1D agonist for migraine. Cephalalgia 1997; 17: 4-14
26. Buzzi MG, Moskowitz MA, Peroutka SJ, et al. Further characterization of the putative 5-HT receptor which mediates blockade of neurogenic extravasation in rat dura mater. Br J Pharmacol 1991; 103: 1421-8
27. Goadsby PJ, Edvinsson L. Sumatriptan reverses the changes in calcitonin gene-related peptide seen in the headache phase of migraine. Cephalalgia 1991; 11 Suppl. 11: 3-4
28. Godsby PJ, Hoskin KL. Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): are brainstein sites therapeutic target in migraine? Pain 1996; 67: 355-9
29. Cumberbatch MJ, Hill RG, Hargreaves RJ. Rizatriptan has central antinociceptive effects against durally evoked responses. Eur J Pharmacol 1997; 328: 37-40
30. Cutler NR, Claghorn J, Sramek JJ, et al. Pilot study of MK-462 in migraine. Cephalalgia 1996; 16: 113-6
31. Solomon GD, Cade RK, Klapper JA, et al. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. Neurology 1997; 49: 1219-25
32. Pilgrim AJ, Blakeborough P. The clinical efficacy of sumatriptan in the acute treatment of migraine. Rev Contemp Pharmacother 1994; 5: 295-309
33. Oral Sumatriptan Dose-Defining Study Group. Sumatriptan an oral dose-defining study. Eur Neurol 1991; 31: 300-5
34. Wilkinson M, Pfaffenrath V, Schoenen J, et al. Migraine and cluster headache - their management with sumatriptan: a critical rewiew of the current clinical experience. Cephalalgia 1995; 15: 337-57
35. Mathew NT, Asgharnejad M, Peykamian M, et al. Naratriptan is effective and well tolerated in the acute treatment of migraine: results of a double-blind, placebo-controlled, crossover study. Neurology 1997; 49: 1485-90
36. 1D receptor agonists for the treatment of migraine attacks. In: Oleson J, Tfelt-Hansen P, editors. Frontiers of headache research headache treatment: trial methodology and new drugs. New York: Raven Press, 1997: 253-6
37. Visser WH, Jaspers NMWH, de Vriend RHM, et al. Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients. Cephalalgia 1996; 16: 264-4
38. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995; 1: 658-60
39. Winner P, Ricalde O, Le Force B, et al. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996; 53: 180-4
40. Jackson NC, on behalf of the Eletriptan Steering Committee. Clinical measures of efficacy, safety and tolerability for the acute treatment of migraine: a comparison of eletriptan) 20-80mg), sumatriptan (100mg) and placebo [abstract]. Neurology 1998; 50 Suppl. 4: A376
41. Brown EG, Endersby CA, Smith RN, et al. The safety and tolerability of sumatriptan: an overview. Eur Neurol 1991; 31: 339-44
42. Diener HC. Substance P antagonist RPR 100893-201 is not effective in human migraine attacks. 6th International Headache Research Seminar; 1995 Nov 19: Copenhagen
43. Goldstein DJ, Wang O, Saper JR, et al. Ineffectiveness of neurokinin-1 antagonist in acute migraine: crossover study. Cephalalgia 1997; 17: 785-90
44. May A, Gijsman HJ, Wallnöfer A, et al. Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain 1996; 67: 375-8
45. Roon K, Diener HC, Ellis P, et al. CP-122,288 blocks neurogenic inflammation, but is not effective in aborting migraine attacks: results of two controlled clinical trials [abstract]. Cephalalgia 1997; 17 (3): 245
46. Hämäläinen ML, Hoppu K, Santavuori P. Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine attacks respond to oral sumatriptan differently from adults? Neurology 1997; 48: 1100-3
47. Lanzi G, Balottin U, Zambrino CA, et al. Guidelines and recommendations for the treatment of migraine in pediatric and adolescent patients. Funct Neurol 1996; 11: 269-75
48. Caers LI, DeBeukelaar F, Amery WK. Flunarizine, a calcium-entry blocker, in childhood migraine, epilepsy, and alternating hemiplegia. Clin Neuropharmacol 1987; 10: 162-8
49. DelBene E, Gatto G, Poggioni M. Clinical and pharmacological investigation in flunarizine treated migrainous children. Collegium Internationale Neuropsychopharmacologicum 1984;51
50. Haemaelaeinen ML, Hoppu K, Sanatvuori PR. Oral dihydroergotamine for therapy-resistant migraine attacks in children. Pediatr Neurol 1997; 2: 14-7
51. Linder SL. Treatment of childhood headache with dihydroergotamine mesylate. Headache 1994; 34: 578-80
52. Saadah HA. Abortive headache therapy with intramuscular dihydroergotamine. Headache 1992; 32: 18-20
53. Diener HC, Limmroth V. The treatment of migraine. Rev Contemp Pharmacother 1994; 5: 271-84
54. Hoffert MJ, Couch JR, Diamond S, et al. Transnasal butorphnol in the treatment of acute migraine. Headache 1995; 35: 65-9
55. Couturier EGM, Hering R, Steiner TJ. Weekend attacks in migraine patients: caused by caffeine withdrawal. Cephalalgia 1992; 12: 99-100
56. van Dusseldorp M, Katan MB. Headache caused by caffeine withdrawal among moderate coffee drinkers switched from ordinary to decaffeinated coffee: a 12-week double-blind trial. BMJ 1990; 300: 1558-9
57. Migraine-Nimodipine European Study Group (MINES). European multicenter trial of nimodipine in the prophylaxis of common migraine (migraine without aura). Headache 1989; 29: 633-8
58. Migraine-Nimodipine European Study Group (MINES). European multicenter trial of nimodipine in the prophylaxis of classic migraine (migraine with aura). Headache 1989; 29: 639-42
59. Holroyd KA, Penzien DB, Cordingley GE. Propranolol in the management of recurrent migraine: a meta-analytic review. Headache 1991; 31: 333-40
60. Peatfield RC, Fozard JR, Rose CF. Drug treatment of migraine. In: Clifford Rose F, editor. Handbook of clinical neurology. Vol. 4 (48): Headache. Amsterdam: Elsevier Science Publishers B.V., 1986: 173-217
61. Stensrud P, Sjaastad O. Comparative trial of Tenormin (atenolol) and Inderal (propranolol) in migraine. Headache 1980; 20: 204-7
62. Tfelt-Hansen P, Standnes B, Kangasniemi P, et al. Timolol vs propranolol vs placebo in common migraine prophylaxis: a double-blind multicenter trial. Acta Neurol Scand 1984; 69: 1-8
63. Freitag FG, Diamond S. Nadolol and placebo comparison study in the prophylactic treatment of migraine. J Am Osteopath Assoc 1984; 84: 343-7
64. van de Ven LLM, Franke CL, Koehler PJ. Prophylactic treatment of migraine with bisoprolol: a placebo-controlled study Cephalalgia 1997; 17: 596-9
65. Olesen J, Tfelt-Hansen P, Welch KMA, editors. The headaches. New York, Raven Press, 1993
66. Markley HG, Chcronis CD, Piepho RW. Verapamil in prophylactic therapy of migraine. Neurology 1984; 34: 973-6
67. Solomon CGD, Steel MJG, Spaccavento CLJ. Verapamil prophylaxis of migraine. JAMA 1983; 250: 2500-2
68. Albers GW, Simon LT, Hamik A, et al. Nifedipine versus propranolol for the initial prophylaxis of migraine. Headache 1989; 29: 214-7
69. Diener HC, Föh M, Iaccarino C, et al. Cyclandelate in the prophylaxis of migraine: a randomized, parallel, double-blind study in comparison with placebo and propranolol. Cephalalgia 1996; 16: 441-7
70. Bousser MG, Chick J, Fuseau E, et al. Combined low-dose acetylsalicylic acid and dihydroergotamine in migraine prophylaxis. Cephalalgia 1988; 8: 187-92
71. Buscaino GA, Sorge F, Bussone G, et al. Preventive treatment of headache with slow-release dihydroergotamine: comparison of dosage protocols. Curr Ther Res 1991; 49: 925-35
72. Scholz E, Gerber WD, Diener HC, et al. Dihydroergotamine versus flunarizine versus nifedipine versus metoprolol versus propranolol in migraine prophylaxis. A comparative study based on time series analysis. In: Clifford Rose F, editor. Advances in headache research. London: John Liey & Co., 1987: 135-45
73. Dichgans J, Diener HC, Gerber WD, et al. Analgetika-induzierter Dauerkopfschmerz. Dtsch Med Wochenschr 1984; 109: 369-73
74. Buring JE, Peto R, Hennekens CH. Low-dose aspirin for migraine prophylaxis. JAMA 1990; 264: 1711-3
75. Grotemeyer K-H, Scharafinski H-W, Schlake H-P, et al Acetylsalicylic acid vs metoprolol in migraine prophylaxis - a double blind cross-over study. Headache 1990; 30: 639-41
76. Diener HC, Hartung E, Chrubasik J, et al. Acetylsalicylic acid in migraine prophylaxis: a double blind study in comparison with metoprolol [abstract]. Cephalalgia 1997; 17 (3): 434
77. Bellavance AJ, Meloche JP. Comparative study of naproxen sodium, pizotyline and placebo in migraine prophylaxis. Headache 1990; 30: 710-5
78. Diamond S. Freitag FG, Gallagher RM, et al. Ketoprofen in the prophylaxis of migraine. Headache Quarterly 1990; 1: 75-7
79. Johnson RH, Hornabrook RW, Lambie DG. Comparison of mefanamic acid and propranolol with placebo in migraine prophylaxis. Acta Neurol Scand 1986; 73: 490-2
80. Mikkelsen B, Pedersen KK, Christiansen LV. Prophylactic treatment of migraine with tolfenamic acid, propranolol and placebo. Acta Neurol Scand 1986; 73: 423-7
81. Sternieri E, Bussone G, Manzone GC, et al. Lornoxicam, a new nonsteroidal anti-inflammatory drug, in migraine prophylaxis: a double-blind multicenter study. Cephalalgia 1991: 11 Suppl. 11: 154-5
82. Couch JR, Hassanein RS. Amitriptyline in migraine prophylaxis. Arch Neurol 1979; 36: 695-9
83. Ziegler DK, Hurwitz A, Hassanein RS. Migraine prophylaxis: a comparison of propranolol and amitriptyline. Arch Neurol 1987; 44: 486-9
84. Hering R, Kurzitzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 1992; 12: 81-4
85. Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology 1994; 44: 647-51
86. Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol 1995; 52: 281-6
87. Silberstein SD. Divalproex sodium in headache: literature review and clinical guidelines. Headache 1996; 36: 547-55
88. Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997; 17: 103-8
89. Peikert A, Wilimzig C, Kühne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 1996; 16: 257-63
90. Pfaffenrath V, Wessely P, Meyer C, et al. Magnesium in the prophylaxis of migraine - a double-blind, placebo-controlled study. Cephalalgia 1996; 16: 436-40